As announced by press release on November 28, 2022, the Board of Directors of iZafe Group AB (publ) ("iZafe" or the "Company") has decided to distribute warrants free of charge to shareholders in the Company. The record date for allotment of warrants of series TO13B has been set to December 23, 2022. The exercise period to subscribe for new shares with the support of warrants of series TO13B will be from and including February 23, 2023, to and including March 8, 2023. The first day of trading in the warrants of series TO13B on Nasdaq First North Growth Market will be on December 28, 2022.
As announced by press release on November 28, 2022, iZafe has completed a directed issue of shares and warrants of series TO13B (the “Directed Issue”). In order to give existing shareholders in the Company the opportunity to compensate for the dilution the Directed Issue entails, the Board of Directors of iZafe has also decided to issue warrants of series TO13B (same series as in the Directed Issue) to the Company, which then are allotted free of charge to the shareholders in the Company.
The record date to receive warrants of series TO13B has been set to December 23, 2022. Therefore, the last day of trading in the Company’s share including the right to receive warrants is December 21, 2022, and the first day of trading in the Company’s share excluding the right to receive warrants is December 22, 2022.
The Company’s existing shareholders will receive one (1) free warrant of series TO13B for every two (2) shares held in the Company on the record date.
Terms and information regarding warrants of series TO13B
Each warrant of series TO13B gives the right to subscribe for one (1) new share in the Company during the period from and including February 23, 2023, to and including March 8, 2023. The subscription price for shares of series B supported by warrants of series TO13B amounts to 70 percent of the volume weighted average price of the Company's share on the Nasdaq First North Premier Growth Market during the period from and including February 9, 2023, to and including February 22, 2023, however, the share's minimum quota value (currently SEK 0.20) and a maximum of SEK 0.30.
41,666,668 warrants of series TO13B are allotted to the investors in the Directed Issue and 76,890,165 warrants of series TO13B are allotted to the shareholders of the Company. In the event of full utilization of warrants of series TO13B, the Company can receive an additional maximum of approximately SEK 35.6 million, depending on the subscription price. If all of the Company's 118,556,833 issued warrants of series TO13B are exercised, the number of shares in the Company will increase by 118,556,833 shares, from 153,780,330 shares to 272,337,163 shares, and the share capital will increase by SEK 23,711,366.60, from SEK 30,756,066.00 to SEK 54,467,432.60. Which entails a total dilution for the Company's existing shareholders of approximately 43.53 percent of the numbers of shares and approximately 42.69 percent of the votes.
Mangold Fondkommission AB is the finacial advisor to iZafe in connection with the warrants of series TO13B.